ClinicalTrials.gg
Sign In
Biological

Human natural killer cell line NK-92 clinical trials

studies test it
3
open now
0
in phase 3
0
first study started
2005

How each study uses human natural killer cell line NK-92 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

Studies by the year they started

3 studies that test it; most in 2005 (1)

Studies that test human natural killer cell line NK-92, by start year
YearStudies
20051
20141
20151

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Leukemia, Myeloid, Acute
1
Leukemia
1
Carcinoma, Merkel Cell
1

Who runs them

Industry 2 · Other 1

ImmunityBio, Inc. (2) · University Health Network, Toronto (1)

Studies

Open first, then newest update. How each study uses human natural killer cell line NK-92 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Given beside what is tested · 1 — human natural killer cell line NK-92 is usual care or a partner of the new treatment

Codes

What other systems call human natural killer cell line NK-92 · ClinicalTrials.gg INT018523

  • UNII (FDA) Y0EW4890B4HUMAN NATURAL KILLER CELL LINE NK-92One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.